Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapy

Trial Profile

Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Final results of safety, efficacy and pharmacokinetic analysis (n=29) presented at the 41st European Society for Medical Oncology Congress.
    • 19 May 2016 Primary endpoint has been met. (Disease control rate), as per an article published in the European Journal of Cancer.
    • 19 May 2016 Results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top